文献速递糖尿病肥胖与代谢综合征

替尔泊肽单药治疗对比度拉糖肽在日本2型糖尿病患者中的疗效与安全性(SURPASS J-mono):一项双盲、多中心、随机、3期试验

Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial.
PubMed 文献 · Lancet Diabetes Endocrinol · 2022-07-30

这项在日本46个中心进行的双盲随机3期试验纳入636例日本2型糖尿病患者,比较替尔泊肽5、10、15 mg与度拉糖肽0.75 mg每周一次治疗52周的疗效与安全性。替尔泊肽在HbA1c降幅和体重减轻方面均优于度拉糖肽,安全性与GLP-1受体激动剂一致。

要点

  • 替尔泊肽5、10、15 mg组52周HbA1c降幅均优于度拉糖肽0.75 mg组(p<0.0001)。
  • 替尔泊肽体重降低呈剂量依赖性,三个剂量组减重均优于度拉糖肽。
  • 最常见治疗中出现的不良事件为恶心、便秘和鼻咽炎。

核心结论

  • 替尔泊肽在血糖控制和体重降低方面优于度拉糖肽。
  • 替尔泊肽的安全性与GLP-1受体激动剂一致,提示其可能成为日本2型糖尿病患者的治疗选择。

研究设计与样本

  • 多中心、随机、双盲、平行、活性药物对照的3期试验,在日本的46个医学研究中心和医院进行。
  • 纳入20岁及以上、已停用口服降糖药单药治疗或初治的2型糖尿病患者。
  • 参与者按1:1:1:1随机分配接受替尔泊肽5、10或15 mg或度拉糖肽0.75 mg每周一次。
  • 按基线HbA1c(≤8.5%或>8.5%)、基线BMI(<25或≥25 kg/m2)和降糖药洗脱情况分层。
  • 主要终点为改良意向治疗人群中第52周HbA1c较基线的平均变化。

主要发现

  • 2019年5月7日至2021年3月31日期间,821例参与者接受资格评估,636例随机分配并至少接受一剂治疗:替尔泊肽5 mg组159例、10 mg组158例、15 mg组160例、度拉糖肽0.75 mg组159例;615例(97%)完成研究,21例(3%)中止。
  • 参与者平均年龄56.6岁(SD 10.3),男性481例(76%)。
  • 第52周HbA1c较基线的最小二乘均值变化:替尔泊肽5 mg组-2.4%(SE 0.1)、10 mg组-2.6%(0.1)、15 mg组-2.8%(0.1)、度拉糖肽组-1.3%(0.1)。
  • 与度拉糖肽相比的估计平均治疗差异:替尔泊肽5 mg组-1.1%(95% CI -1.3至-0.9)、10 mg组-1.3%(-1.5至-1.1)、15 mg组-1.5%(-1.71至-1.4),所有p<0.0001。
  • 体重较基线的最小二乘均值变化:替尔泊肽5 mg组-5.8 kg(SE 0.4;-7.8%)、10 mg组-8.5 kg(0.4;-11.0%)、15 mg组-10.7 kg(0.4;-13.9%),度拉糖肽组-0.5 kg(0.4;-0.7%)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: As the disease progresses, many patients with type 2 diabetes have difficulty in reaching treatment goals. We aimed to assess the efficacy and safety of tirzepatide, a novel GIP and GLP-1 receptor agonist, compared with dulaglutide in Japanese patients with type 2 diabetes. METHODS: This multicentre, randomised, double-blind, parallel, active-controlled, phase 3 trial was conducted in 46 medical research centres and hospitals in Japan. Adults aged 20 years or older with type 2 diabetes who had discontinued oral antihyperglycaemic monotherapy or were treatment-naïve were included. Participants were randomly assigned (1:1:1:1) to receive tirzepatide (5, 10, or 15 mg) or dulaglutide (0·75 mg) once per week using a computer-generated random sequence with an Interactive Web Response System. Participants were stratified based on baseline HbA1c (≤8·5% or >8·5%), baseline BMI (<25 or ≥25 kg/m2), and washout of antidiabetic medication. Participants, investigators, and the sponsor were masked to treatment assignment. The starting dose of tirzepatide was 2·5 mg once per week for 4 weeks, which was then increased to 5 mg in the tirzepatide 5 mg treatment group. For the tirzepatide 10 and 15 mg treatment groups, increases by 2·5 mg occurred once every 4 weeks until the assigned dose was reached. The primary endpoint was mean change in HbA1c from baseline at week 52 measured in the modified intention-to-treat population. This trial is registered with ClinicalTrials.gov, NCT03861052. FINDINGS: Between May 7, 2019, and March 31, 2021, 821 participants were assessed for study eligibility and 636 were randomly assigned to receive at least one dose of tirzepatide 5 mg (n=159), 10 mg (n=158), or 15 mg (n=160), or dulaglutide 0·75 mg (n=159). 615 (97%) participants completed the study and 21 (3%) discontinued. Participants had a mean age of 56·6 years (SD 10·3) and were mostly male (481 [76%]). At week 52, HbA1c decreased from baseline by a least squares mean of -2·4 (SE 0·1) for tirzepatide 5 mg, -2·6 (0·1) for tirzepatide 10 mg, -2·8 (0·1) for tirzepatide 15 mg, and -1·3 (0·1) for dulaglutide. Estimated mean treatment differences versus dulaglutide were -1·1 (95% CI -1·3 to -0·9) for tirzepatide 5 mg, -1·3 (-1·5 to -1·1) for tirzepatide 10 mg, and -1·5 (-1·71 to -1·4) for tirzepatide 15 mg (all p<0·0001). Tirzepatide was associated with dose-dependent reductions in bodyweight with a least square mean difference of -5·8 kg (SE 0·4; -7·8% reduction) for 5 mg, -8·5 kg (0·4; -11·0% reduction) for 10 mg, and -10·7 kg (0·4; -13·9% reduction) for 15 mg of tirzepatide compared with -0·5 kg (0·4; -0·7% reduction) for dulaglutide. The most common treatment-emergent adverse events were nausea (19 [12%] participants in the 5 mg group vs 31 [20%] in the 10 mg group vs 32 [20%] in the 15 mg group all receiving tirzepatide vs 12 (8%) in the group receiving dulaglutide), constipation (24 [15%] vs 28 [18%] vs 22 [14%] vs 17 [11%]), and nasopharyngitis (29 [18%] vs 25 [16%] vs 22 [14%] vs 26 [16%]). The most frequent adverse events were gastrointestinal (23 [4%] of 636). INTERPRETATION: Tirzepatide was superior compared with dulaglutide for glycaemic control and reduction in bodyweight. The safety profile of tirzepatide was consistent with that of GLP-1 receptor agonists, indicating a potential therapeutic use in Japanese patients with type 2 diabetes. FUNDING: Eli Lilly and Company. TRANSLATION: For the Japanese translation of the abstract see Supplementary Materials section.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Inagaki N, Takeuchi M, Oura T, et al. Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial. Lancet Diabetes Endocrinol. 2022. PMID: 35914543. doi:10.1016/S2213-8587(22)00188-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。